Sartorius Stedim (DIM) | Financial Analysis & Statements
Sartorius Stedim Biotech S.A. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
772.2M
Gross Profit
316.9M
41.04%
Operating Income
134.4M
17.40%
Net Income
47.3M
6.13%
Balance Sheet Metrics
Total Assets
8.0B
Total Liabilities
3.9B
Shareholders Equity
4.1B
Debt to Equity
0.93
Cash Flow Metrics
Operating Cash Flow
156.2M
Free Cash Flow
129.4M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Sartorius Stedim Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.0B | 2.8B | 2.8B | 3.5B | 2.9B |
| Cost of Goods Sold | 1.6B | 1.6B | 1.5B | 1.7B | 1.3B |
| Gross Profit | 1.3B | 1.2B | 1.2B | 1.8B | 1.6B |
| Gross Margin % | 45.3% | 43.4% | 44.4% | 52.0% | 53.8% |
| Operating Expenses | |||||
| Research & Development | 133.1M | 144.1M | 129.5M | 132.4M | 110.5M |
| Selling, General & Administrative | 661.3M | 648.5M | 616.2M | 611.9M | 531.7M |
| Other Operating Expenses | 33.4M | 30.0M | 26.1M | 28.3M | 31.8M |
| Total Operating Expenses | 827.8M | 822.6M | 771.8M | 772.6M | 674.0M |
| Operating Income | 539.4M | 397.6M | 470.5M | 1.1B | 883.0M |
| Operating Margin % | 18.2% | 14.3% | 17.0% | 30.2% | 30.6% |
| Non-Operating Items | |||||
| Interest Income | 11.6M | 18.9M | 6.2M | 500.0K | 300.0K |
| Interest Expense | 139.5M | 149.6M | 117.0M | 18.6M | 10.4M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 373.2M | 219.2M | 401.1M | 1.1B | 646.7M |
| Income Tax | 107.3M | 40.7M | 89.0M | 250.5M | 232.4M |
| Effective Tax Rate % | 28.8% | 18.6% | 22.2% | 22.2% | 35.9% |
| Net Income | 266.0M | 178.5M | 312.1M | 879.9M | 414.3M |
| Net Margin % | 9.0% | 6.4% | 11.2% | 25.2% | 14.4% |
| Key Metrics | |||||
| EBITDA | 846.9M | 706.9M | 695.4M | 1.2B | 1.0B |
| EPS (Basic) | - | €1.81 | €3.36 | €9.51 | €4.50 |
| EPS (Diluted) | - | €1.81 | €3.36 | €9.51 | €4.50 |
| Basic Shares Outstanding | - | 96740331 | 92160626 | 92163099 | 92176829 |
| Diluted Shares Outstanding | - | 96740331 | 92160626 | 92163099 | 92176829 |
Income Statement Trend
Sartorius Stedim Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 426.1M | 678.9M | 116.6M | 107.1M | 223.6M |
| Short-term Investments | 8.1M | 9.9M | - | 25.9M | 13.7M |
| Accounts Receivable | 179.8M | 248.5M | 293.8M | 404.6M | 338.9M |
| Inventory | 690.9M | 684.9M | 882.4M | 1.0B | 783.0M |
| Other Current Assets | 76.2M | 65.8M | 66.0M | 89.3M | 63.3M |
| Total Current Assets | 1.4B | 1.7B | 1.4B | 1.7B | 1.5B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 29.5M | 21.0M | 0 | 599.2M | 484.2M |
| Goodwill | 7.3B | 7.4B | 7.4B | 3.1B | 2.3B |
| Intangible Assets | 1.5B | 1.6B | 1.7B | 876.9M | 684.5M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | 3.6M | 2.7M | 2.3M | 700.0K |
| Total Non-Current Assets | 6.5B | 6.5B | 6.3B | 3.4B | 2.5B |
| Total Assets | 8.0B | 8.3B | 7.7B | 5.1B | 4.0B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 277.8M | 310.0M | 257.1M | 250.2M | 251.3M |
| Short-term Debt | 580.7M | 64.6M | 79.1M | 23.9M | 40.4M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 46.9M | 47.4M | 103.1M | 97.2M | 85.3M |
| Total Current Liabilities | 1.4B | 938.8M | 937.3M | 1.0B | 1.0B |
| Non-Current Liabilities | |||||
| Long-term Debt | 2.0B | 2.8B | 3.6B | 1.1B | 585.1M |
| Deferred Tax Liabilities | 375.6M | 358.2M | 399.8M | 178.3M | 125.8M |
| Other Non-Current Liabilities | - | -100.0K | - | 100.0K | - |
| Total Non-Current Liabilities | 2.4B | 3.3B | 4.1B | 1.5B | 1.2B |
| Total Liabilities | 3.9B | 4.2B | 5.1B | 2.6B | 2.2B |
| Equity | |||||
| Common Stock | 19.5M | 19.5M | 18.4M | 18.4M | 18.4M |
| Retained Earnings | 2.6B | 2.5B | 2.4B | 2.2B | 1.4B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 4.1B | 4.0B | 2.7B | 2.5B | 1.7B |
| Key Metrics | |||||
| Total Debt | 2.6B | 2.9B | 3.7B | 1.1B | 625.5M |
| Working Capital | 29.1M | 802.2M | 477.8M | 635.3M | 418.5M |
Balance Sheet Composition
Sartorius Stedim Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 373.2M | 219.2M | 401.1M | 1.1B | 646.7M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -24.9M | 287.0M | 205.4M | -351.7M | -239.7M |
| Operating Cash Flow | 506.3M | 659.8M | 656.4M | 645.8M | 627.1M |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | - |
| Acquisitions | - | 0 | -2.2B | -515.6M | -141.7M |
| Investment Purchases | -4.4M | -100.0K | - | - | -324.0M |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -4.5M | -200.0K | -2.2B | -526.9M | -465.2M |
| Financing Activities | |||||
| Share Repurchases | - | -1.9M | - | - | - |
| Dividends Paid | -67.1M | -67.1M | -132.7M | -116.1M | -62.7M |
| Debt Issuance | 13.3M | 17.3M | 2.6B | 566.8M | 74.2M |
| Debt Repayment | -334.8M | -879.2M | -326.4M | -174.4M | -79.7M |
| Financing Cash Flow | -388.3M | 262.7M | 2.1B | 235.8M | -68.3M |
| Free Cash Flow | 299.0M | 475.3M | 272.8M | 181.7M | 377.9M |
| Net Change in Cash | 113.5M | 922.3M | 510.0M | 354.7M | 93.6M |
Cash Flow Trend
Sartorius Stedim Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
59.45
Forward P/E
26.24
Price to Book
3.86
Price to Sales
5.29
PEG Ratio
26.24
Profitability Ratios
Profit Margin
8.98%
Operating Margin
19.61%
Return on Equity
6.59%
Return on Assets
4.14%
Financial Health
Current Ratio
1.03
Debt to Equity
63.11
Per Share Data
EPS (TTM)
€2.73
Book Value per Share
€42.04
Revenue per Share
€30.71
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| DIM | 15.8B | 59.45 | 3.86 | 6.59% | 8.98% | 63.11 |
| Crossject S.A | 105.6M | - | - | 212.74% | 0.00% | -4.61 |
| Visiomed Group SA | 52.8M | 59.67 | - | 3.64% | 45.95% | 0.32 |
| Spineway S.A | 5.8M | 16.20 | 0.25 | -9.46% | -17.47% | 6.63 |
Financial data is updated regularly. All figures are in the company's reporting currency.